Gilead Sciences (GILD) investor relations material

Oncology pipeline updates

• Trodelvy demonstrated positive data in first-line triple-negative breast cancer, with anticipated approval later this year and ongoing studies in other tumor types, including non-small cell lung cancer (EVOKE-03).

• EVOKE-03 aims to show significant PFS benefit when Trodelvy is added to pembrolizumab in PD-L1 high NSCLC, potentially marking the first meaningful combination benefit in this setting.

• Acquisition of Tubulis brings novel ADC technology with differentiated linker and payload platforms, and frontrunner TUB-040 showed 50-60% objective response and 90% disease control in platinum-resistant ovarian cancer.

• Trodelvy continues to see increased adoption, with a 37% year-over-year growth, reinforcing confidence in its efficacy and tolerability.

Cell therapy and hematology

• Full rights to anito-cel (BCMA CAR T) and the D-Domain binder platform were acquired, supporting expansion into earlier lines of myeloma treatment.

• Early data for anito-cel show deep MRD responses and unprecedented safety, with no severe neurotoxicities or enterocolitis, and regulatory discussions for fourth-line plus approval are ongoing.

• iMMagine-3 study is ongoing for second to fourth-line myeloma, with plans to move into newly diagnosed populations.

Inflammation and immunology (I&I)

• The inflammation portfolio is maturing, with over 10 molecules and three in phase II, including oral α4β7 (GS-1427), IRAK4 inhibitor, and TYK2 for IBD.

• GS-1427 aims to deliver differentiated efficacy and safety with oral convenience, with phase II data expected later this year.

• Combination and monotherapy approaches are being considered for IBD, with backbone therapy development in mind.